Presenting author
Raffaele Migliore
3 presentations
W37. Lumateperone 42 mg in major depressive disorder: Demographic and clinical subgroups efficacy analysis in a phase 3 randomized placebo-controlled trial
T42. Remission with lumateperone 42 mg adjunctive to antidepressant therapy in patients with major depressive disorder: Analysis of short-term and long-term trials
PS01-1101. Lumateperone 42 mg in major depressive disorder: demographic and clinical subgroups efficacy analysis in a phase 3 randomized placebo-controlled trial